MediciNova Given Notice of Monetary Damages Due Under …
MediciNova has a strong track record of securing investigator-sponsored clinical trials funded through government grants. Statements in this press release that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward ...
MediciNova Given Notice of Monetary Damages Due Under …
2 days ago · MediciNova, Inc. is a clinical-stage biopharmaceutical company developing a broad late-stage pipeline of novel small molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases.
MediciNova notified of settlement in Sanofi Novartis litigation
3 days ago · MediciNova (MNOV) was notified by Sanofi (SNY) that the Sanofi/Novartis (NVS) litigation was settled. Accordingly, MediciNova is entitled to receive a certain amount of monetary damages through ...
MediciNova Given Notice of Monetary Damages Due Under …
3 days ago · About Sanofi/Novartis litigation. On March 30,2022, MediciNova, Inc. was notified that Genzyme Corporation, a subsidiary of Sanofi, filed its First Amended Complaint, which included a claim for infringement of U.S. Patent No. 9,051,542, on February 23, 2022 in a lawsuit previously filed against Novartis Gene Therapies, Inc., Novartis Pharmaceutical Corporation, and Novartis AG in the U.S ...
MediciNova +49% MNOV Settlement; Neurogene NGNE -44
2 days ago · Comprehensive suite of tools for trading and investing in biotech stocks. FDA Calendar, PDUFA Date Calendar, Biotech Company Screener and Database and much more
MediciNova on the Brink: Navigating Legal Settlements and …
In a noteworthy turn of events for MediciNova, Inc. a biopharmaceutical company based in La Jolla, California, the firm has received notification regarding monetary damages stemming from a patent settlement involving Sanofi and Novartis. This development, announced on November 11, 2024, indicates that MediciNova stands to gain a financial boost ...
MediciNova Announces Update of Phase 2/3 Clinical Trial of MN …
LA JOLLA, Calif., Oct. 23, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock ...
MediciNova Announces New Data and Results of a Phase 2 …
Nov 19, 2023 · MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology. MediciNova,...
MediciNova Receives Notice of Allowance for New Patent …
Jun 5, 2024 · MediciNova, Inc. is a clinical-stage biopharmaceutical company developing a broad late-stage pipeline of novel small molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases.
MediciNova Receives a Notice of Grant for a New Patent …
LA JOLLA, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock...
- Some results have been removed